TY - JOUR
T1 - Opium use and subsequent incidence of cancer
T2 - results from the Golestan Cohort Study
AU - Sheikh, Mahdi
AU - Shakeri, Ramin
AU - Poustchi, Hossein
AU - Pourshams, Akram
AU - Etemadi, Arash
AU - Islami, Farhad
AU - Khoshnia, Masoud
AU - Gharavi, Abdolsamad
AU - Roshandel, Gholamreza
AU - Khademi, Hooman
AU - Sepanlou, Sadaf G.
AU - Hashemian, Maryam
AU - Fazel, Abdolreza
AU - Zahedi, Mahdi
AU - Abedi-Ardekani, Behnoush
AU - Boffetta, Paolo
AU - Dawsey, Sanford M.
AU - Pharoah, Paul D.
AU - Sotoudeh, Masoud
AU - Freedman, Neal D.
AU - Abnet, Christian C.
AU - Day, Nicholas E.
AU - Brennan, Paul
AU - Kamangar, Farin
AU - Malekzadeh, Reza
N1 - Publisher Copyright:
© 2020 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL
PY - 2020/5
Y1 - 2020/5
N2 - Background: Evidence is emerging for a role of opiates in various cancers. In this study, we aimed to investigate the association between regular opium use and cancer incidence. Methods: This study was done in a population-based cohort of 50 045 individuals aged 40–75 years from northeast Iran. Data on participant demographics, diet, lifestyle, opium use, and different exposures were collected upon enrolment using validated questionnaires. We used proportional hazards regression models to estimate hazard ratios (HRs) and corresponding 95% CIs for the association between opium use and different cancer types. Findings: During a median 10 years of follow-up, 1833 participants were diagnosed with cancer. Use of opium was associated with an increased risk of developing all cancers combined (HR 1·40, 95% CI 1·24–1·58), gastrointestinal cancers (1·31, 1·11–1·55), and respiratory cancers (2·28, 1·58–3·30) in a dose-dependent manner (ptrend<0·001). For site-specific cancers, use of opium was associated with an increased risk of developing oesophageal (1·38, 1·06–1·80), gastric (1·36, 1·03–1·79), lung (2·21, 1·44–3·39), bladder (2·86, 1·47–5·55), and laryngeal (2·53, 1·21–5·29) cancers in a dose-dependent manner (ptrend<0·05). Only high-dose opium use was associated with pancreatic cancer (2·66, 1·23–5·74). Ingestion of opium (but not smoking opium) was associated with brain (2·15, 1·00–4·63) and liver (2·46, 1·23–4·95) cancers in a dose-dependent manner (prend<0·01). We observed consistent associations among ever and never tobacco users, men and women, and individuals with lower and higher socioeconomic status. Interpretation: Opium users have a significantly higher risk of developing cancers in different organs of the respiratory, digestive, and urinary systems and the CNS. The results of this analysis show that regular use of opiates might increase the risk of a range of cancer types. Funding: World Cancer Research Fund International, Cancer Research UK, Tehran University of Medical Sciences, US National Cancer Institute, International Agency for Research on Cancer.
AB - Background: Evidence is emerging for a role of opiates in various cancers. In this study, we aimed to investigate the association between regular opium use and cancer incidence. Methods: This study was done in a population-based cohort of 50 045 individuals aged 40–75 years from northeast Iran. Data on participant demographics, diet, lifestyle, opium use, and different exposures were collected upon enrolment using validated questionnaires. We used proportional hazards regression models to estimate hazard ratios (HRs) and corresponding 95% CIs for the association between opium use and different cancer types. Findings: During a median 10 years of follow-up, 1833 participants were diagnosed with cancer. Use of opium was associated with an increased risk of developing all cancers combined (HR 1·40, 95% CI 1·24–1·58), gastrointestinal cancers (1·31, 1·11–1·55), and respiratory cancers (2·28, 1·58–3·30) in a dose-dependent manner (ptrend<0·001). For site-specific cancers, use of opium was associated with an increased risk of developing oesophageal (1·38, 1·06–1·80), gastric (1·36, 1·03–1·79), lung (2·21, 1·44–3·39), bladder (2·86, 1·47–5·55), and laryngeal (2·53, 1·21–5·29) cancers in a dose-dependent manner (ptrend<0·05). Only high-dose opium use was associated with pancreatic cancer (2·66, 1·23–5·74). Ingestion of opium (but not smoking opium) was associated with brain (2·15, 1·00–4·63) and liver (2·46, 1·23–4·95) cancers in a dose-dependent manner (prend<0·01). We observed consistent associations among ever and never tobacco users, men and women, and individuals with lower and higher socioeconomic status. Interpretation: Opium users have a significantly higher risk of developing cancers in different organs of the respiratory, digestive, and urinary systems and the CNS. The results of this analysis show that regular use of opiates might increase the risk of a range of cancer types. Funding: World Cancer Research Fund International, Cancer Research UK, Tehran University of Medical Sciences, US National Cancer Institute, International Agency for Research on Cancer.
UR - https://www.scopus.com/pages/publications/85083646078
U2 - 10.1016/S2214-109X(20)30059-0
DO - 10.1016/S2214-109X(20)30059-0
M3 - Article
C2 - 32353313
AN - SCOPUS:85083646078
SN - 2572-116X
VL - 8
SP - e649-e660
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 5
ER -